Skip to main content
. Author manuscript; available in PMC: 2009 Jul 8.
Published in final edited form as: Vaccine. 2009 Jan 31;27(15):2171–2176. doi: 10.1016/j.vaccine.2009.01.097

Fig. 1.

Fig. 1

Lymphocyte proliferative responses in subjects immunized with FMP2.1/AS02A or RabAvert®, Paired Day 0 and 90 stimulation indices (SI) of proliferating PBMC from semi-immune Malian adults receiving either the three-dose series of FMP2.1/AS02A (a) half (25µg/0.25 ml) or (b) full (50µg/0.5 ml) doses or (c) comparator RabAvert® vaccine.